Co-amplification of TOP2A and HER2 genes in breast cancer is associated with improved outcomes when treated with anthracyclines, highlighting the enzyme’s role as a predictive biomarker for chemotherapy efficacy (23). This evidence concerns the gene ERBB2 and breast carcinoma.